

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>tiotropium-olodaterol</b>
Brand Name	Inspiolto™ Respimat®
Dosage Form(s)	2.5 mcg/2.5 mcg solution for inhalation
Manufacturer	Boehringer Ingelheim Canada Ltd.
<b>Review Type</b>	<b>New Submission</b>
Use Reviewed	Chronic obstructive pulmonary disease (COPD)
Common Drug Review (CDR)	Yes, CDR recommended: <b>to List with criteria</b> . Visit the CDR website for more details: <a href="https://www.cadth.ca/sites/default/files/cdr/complete/SR0436_complete_Inspiolto-Respimat-Dec_21-15-e.pdf">https://www.cadth.ca/sites/default/files/cdr/complete/SR0436_complete_Inspiolto-Respimat-Dec_21-15-e.pdf</a>
Provincial Review	DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened tiotropium-olodaterol and advised that because tiotropium-olodaterol is similar to some of the other drugs used for the treatment of COPD, the Ministry may accept the CDEC's recommendation for tiotropium-olodaterol.
<b>Drug Coverage Decision</b>	<b>Limited Coverage Benefit</b> . Access the tiotropium-olodaterol criteria from <a href="http://www.gov.bc.ca/pharmacarespecialauthority">www.gov.bc.ca/pharmacarespecialauthority</a>
Date	April 5, 2016
Reason(s)	The Ministry reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, and the Final CDEC Recommendation. <ul style="list-style-type: none"> <li>The tiotropium-olodaterol demonstrated some efficacy advantage compared to its individual components as monotherapy, fluticasone propionate and salmeterol, and placebo.</li> <li>Based on economic considerations and the submitted product price, the drug offers value for money compared to existing drugs for the treatment of COPD.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.